IPO momentum Avalyn recently filed for a US IPO and secured substantial funding, signaling enhanced financial readiness to scale clinical programs, pursue partnerships, and accelerate late-stage development across inhaled therapies for interstitial lung diseases.

Inhaled advantage The core value proposition centers on inhaled formulations of pirfenidone and nintedanib, offering improved tolerability and targeted lung exposure. This creates a compelling sales angle for pulmonology practices and specialty pharmacies seeking differentiated fibrosis treatments.

Strategic leadership Recent appointments to the executive team and board—GC, new directors—indicate a readiness to expand partnerships, licensing deals, and co-development opportunities with larger pharma and biotech collaborators.

Clinical progress Phase 2b MIST trial for AP01 and Phase 1 data for AP02 demonstrate ongoing clinical activity and data generation, opening opportunities for investigator-initiated studies, payer discussions, and early access programs with pulmonology centers.

Market signals Strong investor attention and a high-profile conference presence (ATS and EULAR 2026) suggest growing visibility among clinicians and payers, creating openings for strategic discussions on adoption, reimbursement pathways, and real-world evidence collaborations.